Neurofibromatosis gene
CA 2086334 A1 · Owner: Marchuk, Douglas A. · Inventors: Marchuk, Douglas A.; Andersen, Lone B.; Collins, Francis S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The entire coding region of the gene involved in von Recklinghausen neurofibromatosis (NF1) and a ubiquitously expressed large transcript (NF1LT) of the gene have been identified cloned and, sequenced. With the identification of the NF1 gene and its gene product, nucleic acid probes and antibodies raised to the gene product can be used in a variety of hybridization and immunological assays to screen for NF1 and detect it in its early stages. Conventional and gene therapies can also be developed to treat those afflicted with the disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 28, 1991. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 28, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 28, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.